MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s10198-026-01954-z

Медицинская библиотека · The European journal of health economics : HEPAC : health economics in prevention and care · 2026

Approaches to utility value assessment in NICE technology appraisals of targeted therapies for non-small-cell lung cancer: a critical examination and recommendations.

Westerink Lotte, Postma Maarten Jacobus, van Boven Job Frank Frank, Boersma Cornelis

СтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVES

The aim of this study is to evaluate the application, methodology and consistency of utility values used in National Institute for Health and Care Excellence (NICE) single technology appraisals (STAs) of targeted therapies for advanced or metastatic non-small-cell lung cancer (NSCLC) over the past decade.

METHODS

A review was conducted of NICE STAs of NSCLC targeted therapies from 2012 to 2022, focusing on four key aspects: (1) utility values per health state as defined by the economic model structure; 2) the primary sources of these utility values; (3) the methods used to derive utilities for quality of life, and 4) the application of disutilities or utility decrements.

RESULTS

In the included 16 appraisals for targeted therapies, substantial variation was identified in the application, methodology, and consistency of utility values used in CUAs appraised by NICE over the past decade. Most appraisals used health state-specific utilities, with progression free values primarily derived from clinical trials and progressed disease values more often derived from external literature. Disutilities for adverse events were applied in an inconsistent way and no stratification by age was reported.

CONCLUSION

Enhancing methodological consistency and incorporating up-to-date, representative utility data, particularly for progressed disease and adverse events, would strengthen the robustness, transparency and comparability of NICE technology appraisals of targeted therapies in NSCLC.

Для цитирования: Westerink Lotte, Postma Maarten Jacobus, van Boven Job Frank Frank, Boersma Cornelis. Approaches to utility value assessment in NICE technology appraisals of targeted therapies for non-small-cell lung cancer: a critical examination and recommendations.. The European journal of health economics : HEPAC : health economics in prevention and care. 2026. DOI: 10.1007/s10198-026-01954-z.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.